Optiray (Ioversol)

Ioversol’s iodine atoms have a high atomic number, which absorbs X‑ray photons more effectively than surrounding tissues. After injection, the iodine distributes in the vascular and extracellular spaces, temporarily increasing radiodensity and creating a clearer distinction between structures on imaging studies.

The specific dose of Optiray is determined by the prescribing physician based on the type of imaging study, patient weight, renal function and other clinical factors. Healthcare professionals calculate the appropriate volume to achieve optimal image quality while minimizing risk.

Optiray should only be used during pregnancy or lactation if clearly needed and after a risk‑benefit assessment by the treating physician. Iodinated contrast agents cross the placenta and may enter breast milk, so caution and specialist advice are recommended.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Optiray (ioversol) is a low‑osmolality, non‑ionic contrast medium, offering a favorable safety profile compared with high‑osmolality agents. It provides comparable image enhancement to other low‑osmolality agents such as iohexol or iopamidol, while being associated with fewer incidences of warmth, taste disturbance and allergic reactions.

Optiray should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen, shaken vigorously, or exposed to temperatures above the recommended range, as this could affect the stability of the iodine solution.

Optiray is supplied as a sterile solution for intravenous injection. It is typically administered through a peripheral or central vein using a power injector or manual bolus, according to the imaging protocol and the volume prescribed by the radiologist.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and cardiovascular events like hypotension or arrhythmias. Prompt recognition and management of these reactions are essential.

Optiray is contraindicated in patients with a known hypersensitivity to ioversol or any iodinated contrast media, those with uncontrolled hyperthyroidism, and individuals with severe renal dysfunction where alternative imaging methods are available. Clinicians must evaluate each patient’s medical history before use.